文献速递乳腺癌放疗

3周大分割全乳放疗联合序贯瘤床加量的2期试验5年结果

5-Year Results of a Prospective Phase 2 Trial Evaluating 3-Week Hypofractionated Whole Breast Radiation Therapy Inclusive of a Sequential Boost.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-06-05

该前瞻性2期试验纳入150例0-IIIA期乳腺癌患者,接受3周大分割全乳放疗(36.63 Gy/11次)序贯瘤床加量(13.32 Gy/4次),总疗程15天。5年局部区域控制率97.7%,无4-5级毒性,医生评估美容效果良好或优秀占95%。

要点

  • 5年局部区域控制率97.7%,远处控制率97.9%。
  • 急性2级和3级毒性分别为30%和1%,晚期分别为10%和3%。
  • 医生评估美容效果良好或优秀占95%,患者自报85%仅轻微或无差异。

核心结论

  • 3周大分割全乳放疗联合序贯加量在5年随访中显示优异的局部区域控制和低毒性,美容效果良好。

研究设计与样本

  • 前瞻性2期试验纳入150例0-IIIA期乳腺癌(导管原位癌至T2N2a)患者,146例接受方案治疗,中位年龄54岁,中位随访62个月。

主要发现

  • 5年局部区域控制率为97.7%(95%CI 93.0%-99.3%),远处控制率为97.9%(95%CI 93.6%-99.3%)。
  • 5年乳腺癌特异生存率为99.2%(95%CI 94.6%-99.9%),总生存率为97.3%(95%CI 91.9%-99.1%)。
  • 急性2级和3级毒性发生率分别为30%和1%,晚期2级和3级分别为10%和3%,无4级或5级毒性。
  • 医生评估美容效果良好或优秀占95%,85%患者自报治疗侧与未治疗侧乳房仅有轻微或无差异。

关键数值与推荐

  • 全乳放疗剂量36.63 Gy分11次,每次3.33 Gy,必要时区域淋巴结接受等效剂量。
  • 序贯瘤床加量13.32 Gy分4次,每次3.33 Gy,总治疗15天。

临床怎么用

  • 该方案为目前最短的大分割全乳放疗疗程之一,可用于异质性乳腺癌人群,包括高危特征患者。

局限性

  • 为单臂2期试验,样本量有限,中位随访62个月,需更长期随访和3期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report 5-year outcomes of a phase 2 trial of hypofractionated whole breast irradiation (HF-WBI) completed in 3 weeks, inclusive of a sequential boost. METHODS AND MATERIALS: Women with stage 0-IIIA breast cancer (ductal carcinoma in situ through T2N2a) were enrolled on a prospective, phase 2 trial of accelerated HF-WBI. We delivered a whole breast dose of 36.63 Gy in 11 fractions of 3.33 Gy, with an equivalent dose to the regional nodes when indicated, followed by a tumor bed boost of 13.32 Gy in 4 fractions of 3.33 Gy over a total of 15 treatment days. The primary endpoint was locoregional control; secondary endpoints included acute/late toxicity and physician-assessed and patient-reported breast cosmesis. RESULTS: Between 2009 and 2017, we enrolled 150 patients, of whom 146 received the protocol treatment. Median age was 54 years (range, 33-82) and median follow-up was 62 months. Patients with higher-risk disease comprised 59% of the cohort, including features such as young age (33% ≤50 years), positive nodes (13%), triple-negative disease (11%), and treatment with regional nodal irradiation (11%) and/or neoadjuvant/adjuvant chemotherapy (36%). Five-year estimated locoregional and distant control were 97.7% (95% confidence interval [CI], 93.0%-99.3%) and 97.9% (95% CI, 93.6%-99.3%), respectively. Five-year breast cancer-specific and overall survival were 99.2% (95% CI, 94.6%-99.9%) and 97.3% (95% CI, 91.9%-99.1%), respectively. Acute/late grade 2 and 3 toxicities were observed in 30%/10% and 1%/3% of patients, respectively. There were no grade 4 or 5 toxicities. Physicians assessed breast cosmesis as good or excellent in 95% of patients; 85% of patients self-reported slight to no difference between the treated and untreated breast. CONCLUSIONS: Our phase 2 trial offers one of the shortest courses of HF-WBI; at 5 years of follow-up there continues to be excellent locoregional control and low toxicity with favorable cosmetic outcomes in a heterogeneous cohort of patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gupta A, Khan AJ, Yegya-Raman N, et al. 5-Year Results of a Prospective Phase 2 Trial Evaluating 3-Week Hypofractionated Whole Breast Radiation Therapy Inclusive of a Sequential Boost. Int J Radiat Oncol Biol Phys. 2019. PMID: 31175905. doi:10.1016/j.ijrobp.2019.05.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。